Big data reveals the characteristics of pancreatic tumors in China: pancreatic cancer 'son-in-law'

The incidence of pancreatic cancer, known as the "King of Cancer" in China, increases year by year, the recurrence rate is high after surgery and the mortality rate is high, but the early diagnosis rate is low, the surgical excision rate is low and the drug is inefficient.
At the 10th Shanghai Forum on Pancreatic Cancer and the 5th China Pancreatic Oncology Conference held on December 12, the China Pancreatic Disease Data Center (CPDC) released the latest research data for four years: Among patients undergoing pancreatic cancer surgery in China, only 0.8% have a family history of pancreatic cancer;
the same day's meeting held online and offline simultaneously, from the field of pancreatic disease authoritative medical experts on the "pancreatic cancer precision treatment system construction" "China pancreatic surgery database entry and data mining" and other topics in-depth exchanges and discussions.
, since its establishment in 2017, China's Pancreatic Disease Data Center has brought together data on a large number of pancreatic tumor patients in 88 triplet hospitals in 31 provinces.
148 subject leaders participated in the joint construction, collecting more than 4.8 million structured statistical data information fields through data governance. "Although there is no shortage of clinical cases of pancreatic cancer in China, there is a lack of Chinese of big data and evidence-based medical evidence to standardize and optimize guidelines for the diagnosis and treatment of pancreatic cancer in China, " said Professor Yang Yumer, chairman of the academic committee of the
Congress and director of general surgery at Peking University's First Hospital.
" Yang Yumer told reporters that past clinical experience believes that pancreatic cancer by family genetic factors will be relatively high, but CPDC real-world data show that genetic factors on the incidence of pancreatic cancer is not significant.
is responsible for the development and construction of China's pancreatic disease data center data technology enterprise founder Shagu told reporters that the CPDC construction model draws on the National Cancer Institute of the United States related database to build a shared mechanism and research services model, and according to the actual needs of innovation.
CPDC covers diagnosis, treatment, follow-up of the whole course of diagnosis and treatment information.
AI data processing technology makes information processing faster, more realistic and accurate.
CPDC data show that pancreatic cancer mainly in the elderly, 60-75 years old patients accounted for 53.3% of the total. Professor Wang Liwei, Executive Chairman of the
Conference, Director of the Pancreatic Cancer Diagnosis and Treatment Center of Shanghai Jiao university and Director of oncology at Renji Hospital, affiliated with Shanghai Jiaoda University School of Medicine, said, "The high-quality data of CPDC multi-center and multidisciplinary not only facilitates doctors to more scientifically recognize pancreatic cancer, but also guides the clinical diagnosis and treatment of pancreatic cancer."
professor Lou Wenxuan, deputy head of the Pancreatic Surgery Group of the Chinese Medical Association's Branch of Surgery and director of pancreatic surgery at Sun Yat-sen Hospital affiliated with Fudan University, said in an interview that the pancreas is located at the back of the stomach, there is no specific clinical manifestation of pancreatic cancer in the early stages, and many patients will be mistaken for stomach diseases at first, with low early diagnosis rates.
surgery, open abdominal surgery accounted for more than 80 percent.
data analysis can help doctors find factors that affect patients' survival and quality of life, and try to avoid and mitigate complications after surgery, said Mr. Lou.
treatment of pancreatic cancer, surgery is only one of them, preoperative complementary treatment is essential.
data show that China's postoperative auxiliary treatment completion rate of pancreatic cancer is less than 50%, preoperative complementary treatment is in single digits.
Wang Liwei said in an interview that drug treatment is becoming more and more important in the comprehensive treatment of pancreatic cancer.
20% of patients with local advanced stages are also able to obtain surgery after drug intervention.
As chairman of the Pancreatic Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO) and head of the Pancreatic Oncology Group of the Chinese Medical Association's Oncology Credit Association, Wang Liwei revealed that china's Pancreatic Disease Data Center (CPDC) is compiling data on internal medicine treatment for pancreatic cancer patients, and has included data from the first 36 medical institutionsChinese.
Chen Jing Source: China News Network!--s content presentation ends -- !-- to determine whether the login ends.